Yescarta (axicabtagene ciloleucel) is an autologous chimeric antigen receptor (CAR) T-cell therapy. It is produced by adapting the patient’s own immune cells to recognize and attack specifically targeted cancer cells. Yescarta is FDA-approved to treat adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who have undergone at least 2 previous treatments for their disease.



If you have a Hayes login, click here to view the full report on the Knowledge Center.